Images List Premium Download Classic

Erythropoietin

Erythropoietin-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Therapeutic compositions and methods for disorders associated with neuronal degeneration
Vanderbilt University
February 01, 2018 - N°20180030105

Disclosed are isolated mutant erythropoietin (epo) polypeptides, functional fragment thereof, nucleic acid encoding such peptides, vectors including such nucleic acids and compositions including such peptides and nucleic acids. The mutant epo peptides are unique in that they include a substitution at amino acid position number 76, such as a glutamic acid for arginine substation at position 76.
Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
January 18, 2018 - N°20180016315

The present disclosure provides isolated stabilized epo-derived peptides and their mimics that protect against tissue damage in subjects having diverse forms of neural and non-neural organ system injury, pharmaceutical compositions containing the isolated stabilized epo-derived peptides, methods for treating symptoms of a disease, disorder or condition having an inflammatory or an autoimmune component in a subject in need thereof, and ...
Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
Curna, Inc.
January 11, 2018 - N°20180010131

Oligonucleotide compounds modulate expression and/or function of erythropoietin (epo) polynucleotides and encoded products thereof. Methods for treating diseases associated with erythropoietin (epo) comprise administering one or more oligonucleotide compounds designed to inhibit the epo natural antisense transcript to patients..
Erythropoietin Patent Pack
Download + patent application PDFs
Erythropoietin Patent Applications
Download + Erythropoietin-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Erythropoietin-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Novel tissue protective erythropoietin receptor (nepor) and methods of use
November 02, 2017 - N°20170315128

There is disclosed a molecular composition(s) of a novel tissue protective erythropoietin (epo) binding receptor protein complex, termed nepor. Presence of nepor components on a tumour allows epo to impinge on the survival of associated cells thereby enhancing tumour progression and negatively effecting patient survival.
Inhibitors of hif prolyl hydroxylase
November 02, 2017 - N°20170313718

The present invention concerns compounds of formula i or a pharmaceutically acceptable salt thereof which inhibit hif prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.. .
Novel compounds supports hematopoietic stem cells and red blood cells
The Board Of Regents Of The University Of Texas System
October 26, 2017 - N°20170304240

The present disclosure relates to methods of using a compound to induce regeneration of hematopoietic stem cells or increase the recovery of red blood cells. In some aspects, the present methods can be used to with or in place of erythropoietin in patients to mitigate the side effects of erythropoietin..
Erythropoietin Patent Pack
Download + patent application PDFs
Erythropoietin Patent Applications
Download + Erythropoietin-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Erythropoietin-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Inhibitors of hif prolyl hydroxylase
Msd R&d (china) Co., Ltd.
August 24, 2017 - N°20170240555

The present invention concerns a compound of formula i or a pharmaceutically acceptable salt thereof, which inhibit hif prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.. .
Substituted pyrimidines as inhibitors of hif prolyl hydroxylase
Merck Sharp & Dohme Corp.
August 24, 2017 - N°20170240513

The present invention concerns compounds of formula i that inhibit hif prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.. .
Substituted pyridine inhibitors of hif prolyl hydroxylase
Merck Sharp & Dohme Corp.
August 24, 2017 - N°20170240511

The present invention concerns compounds of formula i that inhibit hif prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.. .
Inhibitors of hif prolyl hydroxylase
Msd R&d (china) Co., Ltd.
August 17, 2017 - N°20170233412

The present invention concerns compounds of formula i or pharmaceutically acceptable salts thereof, which inhibit hif prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.. .
Inhibitors of hif prolyl hydroxylase
Msd R&d (china) Co., Ltd.
August 10, 2017 - N°20170226120

The present invention concerns compounds of formula i or pharmaceutically acceptable salts thereof, which inhibit hif prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.. .
Methods of treating cognitive impairment
University Of South Florida
July 06, 2017 - N°20170189490

The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (flt3) ligand, interleukin-6 (il-6), macrophage migration inhibitory factor (mif), interleukin-1 (il-1), interleukin-3 (il-3), erythropoietin (epo), vascular endothelial growth factor a (vegf-a), hypoxia-inducible ...
Compositions and methods of preventing erythropoietin associated hypertension
June 22, 2017 - N°20170173150

The invention also provides a method of reducing hypertension in a mammal receiving epo, and pharmaceutical compositions containing a soluble epo-bp and/or a recognition protein that binds epo receptor on an extracellular soluble portion of the epo receptor.. .
Erythropoietin Patent Pack
Download + patent application PDFs
Erythropoietin Patent Applications
Download + Erythropoietin-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Erythropoietin-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Method for preparing recombinant glycoprotein having high sialic acid content, through glycosphingolipid synthesis cycle control
Korea Advanced Institute Of Science And Technology
May 11, 2017 - N°20170129932

The present invention relates to a method for preparing a recombinant cell line producing recombinant glycoproteins having a high sialic acid content by inhibiting glycosphingolipid (gsl) biosynthesis pathway in a cell line producing recombinant glycoproteins. Particularly, the present invention produces erythropoietin (epo), containing a high content of sialic acid in a cell, from a cell line, which induces cgt inhibition ...
Derivatisation of erythropoietin (epo)
Lipoxen Technologies Limited
May 04, 2017 - N°20170119893

The present invention relates to a compound which is a polysaccharide derivative of epo, or of an epo like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds..
Use of negative functional modulators of erythropoietin for therapy
Andremacon S.r.l.
April 27, 2017 - N°20170114132

The invention relates to negative functional modulators of erythropoietin (epo) for use in the treatment of cancers, in the therapy of autoimmune -based and non-autoimmune based chronic inflammatory diseases, and in the treatment of patients under-going organ or tissue transplant, or for the treatment of hemophilic arthropathy, hemophilia a and b, von willebrand disease, angiodysplasia, proliferative disorders and neurological diseases ...
Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
Novagen Holding Corporation
April 27, 2017 - N°20170114110

A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo compared to naturally occurring or recombinant native human erythropoietin.
Liquid pharmaceutical composition of conjugated erythropoietin
Intas Pharmaceuticals Ltd.
April 27, 2017 - N°20170112901

A liquid pharmaceutical composition having a conjugated erythropoietin, buffer, sugar, tonicity modifier and amino acid as an aggregation inhibitor. The liquid pharmaceutical composition provides a stable pharmaceutical composition which encompasses conjugated erythropoietin, acetate buffer, sucrose, arginine and sodium chloride which is maintained at a ph of about 4.9 to 5.3..
Tetrameric cytokines with improved biological activity
Ibc Pharmaceuticals, Inc.
March 02, 2017 - N°20170056516

The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-mab dnl complex comprises an igg antibody attached to two ad (anchor domain) moieties and four cytokines, each attached to a ddd (docking and dimerization domain) moiety.
Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications
Remedor Biomed Ltd.
March 02, 2017 - N°20170056480

A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm2 wound tissue of erythropoietin and about 100-300 mg per cm2 wound tissue of fibronectin, thereby promoting wound healing or connective tissue reconstruction or ...
Novel nitrogen-containing heteroaryl compounds and methods of use thereof
Fibrogen, Inc.
February 09, 2017 - N°20170035747

The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.. .
Loading